Lori J. Wirth, MD, discusses the promising results seen so far with LOXO-292 in patients with thyroid cancer.
Lori J. Wirth, MD, associate professor of medicine at Harvard Medical School and medical director of the Center for Head and Neck Cancers at Massachusetts General Hospital, discusses the promising results seen so far with LOXO-292 in patients with thyroid cancer.
LOXO-292 has been well-tolerated so far with few significant adverse events (AEs). Most AEs have only been grade 1 and grade 2. The recommended dose found in the dose escalation trial is now being moved to an expansion cohort.
For patients withRET-fusion tumors in patients with nonsmall cell lung cancer and differentiated thyroid cancer, the response rate has been around 77%, while patients withRET